Monte Rosa Therapeutics, Inc. Common Stock
GLUEMonte Rosa Therapeutics, Inc. develops targeted protein degradation therapies aimed at treating difficult-to-drug diseases. Focused on innovative approaches, the company leverages its proprietary technologies to discover and develop novel therapeutics for unmet medical needs.
Company News
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to clo...
Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.
Monte Rosa Therapeutics announced CEO Markus Warmuth will participate in multiple healthcare investor conferences in November and December 2025, presenting the company's molecular glue degrader (MGD) research and developments.
Monte Rosa Therapeutics presented preclinical data on MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat multiple autoimmune and inflammatory diseases like systemic lupus erythematosus and rheumatoid arthritis in mouse models.
Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.
